Results 111 to 120 of about 10,318 (317)

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials [PDF]

, 2020
Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly, Anand Thakarakkattil Narayanan Nair, Colin N.A. Palmer, Viswanathan Mohan, Ewan R. Pearson   +6 more
openalex   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity

Translation
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle changes and drug therapy can improve weight loss.
Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser   +4 more
openaire   +3 more sources

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations

Diabetology & Metabolic Syndrome
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the ...
Baixuan Shen, Wanying Wang, Yuanhui Guo, Zilong Chen, Chuanxin Liu, Jiarui Huang, Ying Li   +6 more
doaj   +1 more source

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes

Frontiers in Pharmacology
Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications.
Yongru Chen, Jingxian Chen, Jingxian Chen, Shuo Zhang, Shuo Zhang, Dan Zhu, Feiying Deng, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou   +17 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

Drug Design, Development and Therapy, 2023
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People’s Republic of China ...
Fang P, Ye Z, Li R, She D, Zong G, Zhang L, Xue Y, Zhang K   +7 more
doaj  

Complete Skin Remission of Lichen Planus With Tirzepatide

Australasian Journal of Dermatology, EarlyView.
Harmeet Bhullar, Emma Veysey, Tanya Bohl, Saurabh Prakash, Sarah Smithson   +4 more
wiley   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis [PDF]

, 2019
GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) have been associated with improved glycemic control, body weight loss and favorable changes in cardiovascular risk factors and outcomes. We conducted a systematic review and meta-analysis to
Brescia F., Castellana M., Cignarelli A., Giorgino F., Laviola L., Natalicchio A., Perrini S.   +6 more
core   +1 more source